MicroPort CardioFlow Medtech Corporation has completed its acquisition of MicroPort Cardiac Rhythm Management Limited and its subsidiaries, which are now indirect subsidiaries of the company. The transaction was finalized on December 19, 2025, following the satisfaction or waiver of all conditions precedent under the merger agreement. With this completion, the company expands its business scope from interventional treatment of structural heart diseases to include cardiac rhythm management, establishing a diversified product platform in the Total Cardio field. The integration is expected to enhance the group’s global market presence, competitiveness, and risk resilience, while enabling the delivery of comprehensive management solutions for heart failure across all causes and stages of the disease.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microport Cardioflow Medtech Corporation published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251221-11962656), on December 21, 2025, and is solely responsible for the information contained therein.
Comments